Our Team

With thought-leaders from finance, healthcare and psychedelics, Psych Capital is the UK’s and Europe’s primary incubator in psychedelic science and healthcare.

Board of Directors

William Potts

Co-Founder & CIO

William has been an active investor in psychedelics healthcare since 2020, being a lead investor in Awakn Life Sciences at an early stage. He brings an extensive network of high net worth and institutional investors to the table.

William has been specifically focused on the healthcare sector for a number of years now, including co-founding European cannabis investment firm, Goodplant Ventures in 2021.

Stephen Murphy

Co-Founder & Executive director

Co-founder of Psych Capital Plc.He founded PSYCH in early 2019 to provide data and intelligence on the emerging psychedelics industry. He is also CEO and co-founder of Prohibition Holdings which owns some of the cannabis industry’s best-known B2B companies and brands including Prohibition Partners, Business of Cannabis, Cannabis Europa and Atalis.

Stephen’s background is in technology, digital media and corporate finance, including roles with Sony Pictures, Unilever and Diageo.

Joseph Colliver

Non-Executive Chairman

Joseph is a Fellow Chartered Accountant with a broad range of finance, commercial and management consultancy experience. Before joining Sativa Group Inc. as CFO and main board director, Joseph was a Director of Consulting at Kantar Consulting, part of WPP plc, CFO at WPP’s Kantar Futures, and previously Global Commercial Director of WPP’s TNS, a $1.8 billion turnover marketing agency.

Management Team

William Potts

Co-Founder & CIO

William has been an active investor in psychedelics healthcare since 2020, being a lead investor in Awakn Life Sciences at an early stage. He brings an extensive network of high net worth and institutional investors to the table.

William has been specifically focused on the healthcare sector for a number of years now, including co-founding European cannabis investment firm, Goodplant Ventures in 2021.

Stephen Murphy

Co-Founder & Executive director

Co-founder of Psych Capital Plc.He founded PSYCH in early 2019 to provide data and intelligence on the emerging psychedelics industry. He is also CEO and co-founder of Prohibition Holdings which owns some of the cannabis industry’s best-known B2B companies and brands including Prohibition Partners, Business of Cannabis, Cannabis Europa and Atalis.

Stephen’s background is in technology, digital media and corporate finance, including roles with Sony Pictures, Unilever and Diageo.

Christina Lundberg

Managing Director

10 + years in leadership roles in tech startups across London, SF and Stockholm within business development and strategic communications. First employee at iZettle in the UK (acquired by PayPal for $2.2B).

With postgraduate studies in Psychology & Neuroscience, and working with coaching/ consulting start-up founders in the AI space, Christina’s passion lies in the intersection of mental health and scaling hyper-growth companies.

Beriwan Ceren

Associate

Worked on the launch of multiple start-ups including DoinGud (NFT creator’s platform), Tutorbloc (ed-tech marketplace she co-founded and secured Innovate UK funding), and the psychedelic venture studio, Beckley Waves.

Beriwan centres upon research and investments at Psych Capital, bringing her passion for driving entrepreneurial impact across the industry.

Corporate Advisory Board

Dr Anne Katrin Schlag

Advisor

A Chartered Psychologist and Head of Research at Drug Science (the leading independent scientific body on drugs in the UK).

Leads the research for the Drug Science Medical Cannabis and Psychedelics Working Group.,including the improvement of patient access, with expertise across science and policy making, risk perception, risk management and risk communication.

Honorary Fellowships at Imperial College London and King’s College London.

Stephen O’Hara

Advisor

A microbiologist with over 50 publications, 70+ patents, and numerous book chapters.

Both scientist and a successful entrepreneur with a strong track record of identifying opportunities, raising finance, commercialising products, and taking a number of companies to exit by IPO or trade sale. E.g. as the Founder of Acolyte Biomedica which exited 32X to 3M healthcare in 2007.

Founder and Chief Executive of Optibiotix Health Plc and regular investment advisor to institutional investors.

Peter Reitano

Advisor

Serial entrepreneur and investor, who’s been an early mover in the cannabis and psychedelics industries.

Built, advised, raised for, and sold multiple ventures, including High12, one of Canada’s top cannabis CPG companies. Founder of Gwella, a wellness company with a focus on mushrooms and psychedelics.

An experienced growth hacker, he’s worked directly with world-leading Fortune 500 brands and award winning agencies in Europe, Australia, Canada and the US.

Spencer Harman

Advisor

Investment banker with 25 years experience across the US and UK.

Managing Director at Stifel in New York and previously a board member of Stifel Nicolaus Europe Ltd and Head of the European fixed income business.

Previous director or vice president roles at Knight Capital Group, UBS, Barclays Capital, RBC Capital Markets and Scotiabank.